Amgen to acquire ChemoCentryx for $52/share (~$3.7B) including TAVNEOS

AMGEN INC

Amgen will pay $52 per share in cash, enterprise value ~$3.7B; deal unanimously approved by both boards.
TAVNEOS (avacopan) is a first-in-class oral C5aR inhibitor approved Oct 2021 for ANCA-associated vasculitis; Q1 2022 US sales $5.4M.
Transaction expected to close Q4 2022, subject to ChemoCentryx stockholder approval, HSR clearance, and other conditions.
ChemoCentryx must pay Amgen a termination fee of ~$119M if it terminates for a superior proposal or under certain circumstances.
Acquisition includes early-stage pipeline: three inflammatory disease candidates and an oral checkpoint inhibitor for cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.